Archimed
 
 
 
  • About Us
  • Fund
  • Support
  • Return
  • Our Companies
  • left
    • About Us
    • Our Companies
    • Sustainability & Impact
  • Fund
    • Our Investment Strategy
    • Our Investors
    • Our Funds
  • Support
    • Our Value Creation Approach
    • Our Team and Network
  • Return
    • Return to Investors
    • Return to People
    • Return to Society
  • right
    • News
    • JOIN OUR TEAM
    • Investor Portal
    • Contact

NEWS

Our Latest News

ARCHIMED acquires Groupe Laboratoire Rivadis, a leading player in baby and elderly skincare products

Global private equity healthcare specialist ARCHIMED further expands its presence in the Consumer Health sector with the acquisition of Groupe Laboratoire Rivadis.

ARCHIMED acquires Groupe Laboratoire Rivadis, a leading player in baby and elderly skincare products

ARCHIMED refinances Ad-Tech less than a year after purchase, returning more than a third of investment to shareholders

 October

 20, 

2021

ARCHIMED’s NAMSA returns more than a third of investment

 October

 7, 

2021

ARCHIMED backs Xpress Biologics, a leading provider of plasmid DNA for advanced therapy medicinal products

 October

 5, 

2021

ARCHIMED closes MED III at €650 million hard cap in less than two months

 August

 5, 

2021

ARCHIMED’s NAMSA consolidates leadership in Medical Device Clinical Research, buying Clinlogix

 August

 2, 

2021

ARCHIMED buys Stragen Pharma, a leader in the development, registration and distribution of hard-to-make generic drugs

 June

 24, 

2021

< 1 … 6 7 8 9 10 … 17 >
368
  • ARCHIMED © 2026
  • Our Eco-Design Approach
  • Legal Notice
  • SFDR Disclosures
  • Contact Us
  • LinkedIn
  • Manage your cookies
  • .
    Go top

    Back to top